Leeds surgical technology company gains access to Chinese market

A Leeds surgical technology company achieves success in China, after its debut product gained regulatory approval.

TissuePatch, created by the Yorkshire-based Tissuemed, is the only synthetic, self-adhesive patch for preventing leaks during and after surgery.

Tissuemed chief executive, David Mandley, says: "China holds great potential for us - for example, the country has 12,000 practicing neurosurgeons alone."

While TissuePatch took five years to develop, the synthetic cover which protects patient's stiching and stapling from further injury, is now exported to 25 countries.

Now Tissuemed have been given the green light by by China’s Federal Drug Administration (CFDA), they will work alongside Chamber International’s China specialist, Matthew Grandage to ensure communicative links with the medical devices market.

While the synthetic surgery cover can be used in general surgery, a Chinese hospital in the Sichuan province who were the first to use Tissuepatch, debuted the device during a thoracic procedure.

Various different surgical specialisms use TissuePatch already, but the CFDA's approval will only encourage their market growth.

The Leeds company was founded in 1985 by two cardio-thoracic surgeons at the Cardiac Research Centre at Killingbeck Hospital.

Now Tissuemed have 15 staff, internationally recognised and export more than half of their £1.1m turnover.

Comments are closed.